Tobias J. Derfuss

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 172 publications

Quantitative and molecular adjudication of BioFire FilmArray and QIAstat-Dx discordance in meningitis/encephalitis diagnostics.

Quantitative and molecular adjudication of BioFire FilmArray and QIAstat-Dx discordance in meningitis/encephalitis diagnostics.

Journal: Microbiology spectrum

Published: September 02, 2026

Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.

Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 04, 2026

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis.

Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis.

Journal: Science translational medicine

Published: July 22, 2026

Retinal layers prognosticate cognitive progression independent of relapse activity in multiple sclerosis.

Retinal layers prognosticate cognitive progression independent of relapse activity in multiple sclerosis.

Journal: Journal of neurology

Published: May 27, 2026

Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: May 13, 2026

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 23, 2026

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

Journal: Neurodegenerative disease management

Published: April 07, 2026

Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.

Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.

Journal: Journal of neurology

Published: March 30, 2026

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Journal: Research square

Published: March 27, 2026

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Journal: Research square

Published: March 27, 2026

Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models.

Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models.

Journal: Nature communications

Published: March 11, 2026

Showing 1-12 of 172

Last Updated: 09/26/2026